Inhibikase Therapeutics to Participate at the H.C. Wainwright Global Investment Conference
Rhea-AI Summary
On May 10, 2022, Inhibikase Therapeutics (Nasdaq: IKT) announced that Dr. Milton Werner, President & CEO, will present at the H.C. Wainwright Global Investment Conference in Miami Beach, FL, scheduled for May 25, 2022 at 2:30 pm ET. The company is focused on developing therapies for Parkinson's disease and related disorders, with a lead program targeting the treatment of neurodegeneration. Inhibikase's multi-therapeutic pipeline includes IkT-148009 and other drug delivery technologies, aimed at enhancing patient experience.
Positive
- None.
Negative
- None.
News Market Reaction – IKT
In the trading session that priced this news, IKT declined 11.10%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON and ATLANTA, May 10, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that Dr. Milton Werner, Ph.D., the Company's President & Chief Executive Officer will present at the upcoming H.C. Wainwright Global Investment Conference being held in Miami Beach, FL on May 25, 2022 at 2:30 pm ET.
About Inhibikase (www.inhibikase.com)
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Inhibikase's multi-therapeutic pipeline focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain. Its multi-therapeutic pipeline is pursuing Parkinson's-related disorders of the brain and GI tract, orphan indications related to Parkinson's disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent Imatinib that the Company believes will provide a better patient experience with fewer on-dosing side-effects. The Company's RAMP™ medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.
Social Media Disclaimer
Investors and others should note that we announce material financial information to our investors using our investor relations website, press releases, SEC filings and public conference calls and webcasts. The Company intends to also use Twitter, Facebook, LinkedIn and YouTube as a means of disclosing information about the Company, its services and other matters and for complying with its disclosure obligations under Regulation FD.
Contacts:
Company Contact:
Milton H. Werner, PhD
President & CEO
678-392-3419
info@inhibikase.com
Investor Relations:
Alex Lobo
SternIR, Inc.
alex.lobo@sternir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/inhibikase-therapeutics-to-participate-at-the-hc-wainwright-global-investment-conference-301542540.html
SOURCE Inhibikase Therapeutics, Inc.